Plasma levels of ANGPTL8 are known to be higher in atherosclerotic patients, resulting in plasma LPL inhibition and the build-up of circulating lipoproteins, both of which contribute to inflammation and the pathogenesis of atherosclerosis. Here, ANGPTL8 is linked to atherosclerosis.